Khayat A S, Antunes L M, Guimarães A C, Bahia M O, Lemos J A R, Cabral I R, Lima P D L, Amorim M I M, Cardoso P C S, Smith M A C, Santos R A, Burbano R R
Centro de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brazil.
Clin Exp Med. 2006 Mar;6(1):33-7. doi: 10.1007/s10238-006-0091-x.
Very satisfactory results have been obtained with the treatment of sickle cell anaemia with hydroxyurea (HU), an antineoplastic drug. This is because it significantly increases the levels of foetal haemoglobin. Nevertheless, inadequate dosages or prolonged treatment with this pharmaceutical can provoke cytotoxicity or genotoxicity, increasing the risk of neoplasia. We monitored patients under treatment with HU for possible mutagenic effects, through cytogenetic tests (mitotic index and chromosome aberrations) for one year. Checking at two-month intervals, the cytotoxic effect was not evident. There was no evidence of genotoxicity under the conditions of our experiment. However individuals treated with HU should be constantly monitored, as an absence of genotoxicity could be transitory; the mitotic index should also be observed, as an indicator of cytotoxicity.
使用抗肿瘤药物羟基脲（HU）治疗镰状细胞贫血已取得非常令人满意的结果。这是因为它能显著提高胎儿血红蛋白水平。然而，这种药物剂量不足或长期治疗可能会引发细胞毒性或基因毒性，增加肿瘤形成的风险。我们通过细胞遗传学检测（有丝分裂指数和染色体畸变）对接受HU治疗的患者进行了为期一年的可能诱变效应监测。每隔两个月进行检查，细胞毒性作用并不明显。在我们的实验条件下没有基因毒性的证据。然而，接受HU治疗的个体应持续监测，因为基因毒性的缺失可能是暂时的；还应观察有丝分裂指数，作为细胞毒性的指标。
